PhaseRx (PZRX) Given Daily Coverage Optimism Rating of 0.01
Media headlines about PhaseRx (NASDAQ:PZRX) have been trending somewhat positive this week, according to Accern Sentiment. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. PhaseRx earned a news sentiment score of 0.01 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.943263214173 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
- PhaseRx to Present at 5th International mRNA Conference (finance.yahoo.com)
- PhaseRx, Inc. (PZRX) Scheduled to Post Quarterly Earnings on Monday (americanbankingnews.com)
- U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.14% (uk.investing.com)
- Mid-Morning Market Update: Markets Mostly Higher; Amazon Beats Q3 Views (fxstreet.com)
- PhaseRx Receives Delisting Notice from Nasdaq and Evaluates Listing Options (finance.yahoo.com)
Separately, Laidlaw lowered shares of PhaseRx from a “buy” rating to a “neutral” rating in a research note on Friday, October 13th.
PhaseRx (NASDAQ:PZRX) last announced its quarterly earnings data on Thursday, August 10th. The company reported ($0.30) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.09).
TRADEMARK VIOLATION NOTICE: This news story was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://theolympiareport.com/2017/11/01/phaserx-pzrx-given-daily-coverage-optimism-rating-of-0-01.html.
PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood.
Receive News & Ratings for PhaseRx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseRx Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.